Rodriguez L H, Johnson D E
Urology. 1978 Apr;11(4):344-6. doi: 10.1016/0090-4295(78)90228-5.
Thirty-two patients with metastatic renal cell carcinoma were treated with cisplatinum, 100 mg./M2 at twenty-eight-day intervals. The drug was given intravenously after first assuring adequate hydration. Response could be determined in 23 patients. There were no partial or complete responses, although 1 patient had less than a 50 per cent reduction in pulmonary lesions and 7 patients had stabilization of their disease for periods ranging from three to seven months. It is concluded that the therapeutic value of cisplatinum in the treatment of advanced renal carcinoma is negligible when used as a single agent.
32例转移性肾细胞癌患者接受顺铂治疗，剂量为100mg/M²，每28天一次。在首先确保充分水化后，药物通过静脉注射给药。23例患者可确定疗效。虽有1例患者肺部病灶缩小不到50%，7例患者病情稳定3至7个月，但无部分缓解或完全缓解情况。结论是，顺铂作为单一药物用于治疗晚期肾癌时，其治疗价值可忽略不计。
